E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Crohn's disease
|
Morbo di Crohn |
|
E.1.1.1 | Medical condition in easily understood language |
A form of inflammatory bowel disease |
Malattia infiammatoria dell'intestino |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011401 |
E.1.2 | Term | Crohn's disease |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objectives of this open-label extension-safety monitoring (OLE-SM) study are as follows: Part 1 (Open-Label Extension; OLE) ¿ To assess the long-term safety and efficacy of etrolizumab in patients eligible for Part 1 (OLE) Part 2 (Safety Monitoring; SM) ¿ Progressive multifocal leukoencephalopathy (PML) safety monitoring in patients who have stopped study treatment Safety Objectives The other safety objectives for this study are as follows: Part 1 (OLE) ¿ To evaluate the incidence, rate per subject-year, and severity of infection-related adverse events ¿ To evaluate the incidence and rate per subject-year of malignancies ¿ To evaluate the incidence and severity of hypersensitivity reactions ¿ To evaluate the incidence and the clinical significance of antitherapeutic antibodies (ATAs) |
Gli obiettivi di questo studio di estensione in aperto e di monitoraggio della sicurezza (OLE-SM) sono i seguenti: Parte 1 (Estensione in aperto [Open-Label Extension, OLE]) - Valutare la sicurezza e l¿efficacia a lungo termine di etrolizumab nei pazienti idonei alla Parte 1 (OLE) Parte 2 (Monitoraggio della sicurezza [Safety Monitoring, SM]) - Monitoraggio della sicurezza associato alla leucoencefalopatia multifocale progressiva (Progressive Multifocal Leukoencephalopathy, PML) nei pazienti che hanno interrotto il trattamento dello studio Obiettivi di sicurezza Gli altri obiettivi di sicurezza per questo studio sono i seguenti: Parte 1 (OLE) - Valutare l¿incidenza, il tasso per soggetto all¿anno e la gravit¿ degli eventi avversi correlati all¿infezione - Valutare l¿incidenza e il tasso per soggetto all¿anno di neoplasie maligne - Valutare l¿incidenza e la gravit¿ delle reazioni da ipersensibilit¿ - Valutare l¿incidenza e l¿importanza clinica degli anticorpi antiterapeutici (ATA) |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Non applicabile |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Part 1 Open-label Extension: -Patients previously enrolled in etrolizumab Phase III study GA29144 who meet the eligibility criteria for open-label etrolizumab as described in the protocol Part 2 Safety Monitoring: -Patients who participated in etrolizumab Phase III study GA29144 and are not eligible or choose not to enter Part 1 -Patients who transfer from Part 1 -Completion of the 12-week safety follow-up period prior to entering |
Parte 1 (OLE) • Pazienti precedentemente arruolati nello studio di fase III GA29144 che presentano i criteri di eleggibilità per lo studio in aperto come descritto nel protocollo PARTE 2 (SM) • Pazienti che hanno partecipato allo Studio di fase II GA29144 e che non sono idonei o hanno deciso di non arruolarsi nella Parte 1 (OLE) • Pazienti che provengono dalla Parte 1 (OLE) di questo protocollo • Completamento del periodo di follow-up di sicurezza di 12 settimane prima dell'ingresso |
|
E.4 | Principal exclusion criteria |
Part 1 Open-label Extension: - Any new, significant, uncontrolled condition Part 2 Safety Monitoring: - Non ci sono criteri di esclusione |
Parte 1 OLE: - Qualsiasi nuova, significativa condizione non controllata Parte 2 SM: - Non ci sono criteri di esclusione
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The efficacy outcome measures: • CDAI remission assessed at 12-week intervals during Part 1 (OLE) • PRO2 remission assessed at 12-week intervals during Part 1 (OLE) • Simplified Endoscopic Index for Crohn's disease (SES-CD) score assessed at Week 108 or at early withdrawal, if prior to Week 108, during Part 1 (OLE) Safety Outcome Measures Part 1 (OLE) • Incidence and severity of adverse events • Incidence of serious adverse events • Incidence, rate per subject-year, and severity of infection-related adverse events • Incidence of serious infection-related adverse events • Incidence and severity of injection-site reactions • Incidence of adverse events leading to etrolizumab discontinuation • Incidence of laboratory abnormalities • Incidence and rate per subject-year of malignancies • Incidence of ATAs to etrolizumab • Incidence and severity of hypersensitivity reaction events Part 2 (SM) • Incidence of suspected or confirmed PML events |
Misure di esito relative all’efficacia: Le misure di esito relative all’efficacia per questo studio sono le seguenti: - Remissione secondo il punteggio CDAI valutata a intervalli di 12 settimane durante la Parte 1 (OLE) - Remissione secondo il punteggio PRO2 valutata a intervalli di 12 settimane durante la Parte 1 (OLE) - Punteggio endoscopico semplificato per il morbo di Crohn (SES-CD) valutato alla Settimana 108 o al ritiro anticipato, se precedente alla Settimana 108, durante la Parte 1 (OLE) Misure di esito relative alla sicurezza Parte 1 (OLE) - Incidenza e gravità degli eventi avversi - Incidenza degli eventi avversi gravi - Incidenza, tasso per soggetto all’anno e gravità degli eventi avversi correlati all’infezione - Incidenza degli eventi avversi gravi correlati all’infezione - Incidenza e gravità delle reazioni nel sito dell’iniezione - Incidenza degli eventi avversi che hanno portato alla sospensione di etrolizumab - Incidenza delle anomalie di laboratorio - Incidenza e tasso per soggetto all’anno di neoplasie maligne - Incidenza di ATA per etrolizumab - Incidenza e gravità delle reazioni da ipersensibilità Parte 2 (SM) - Incidenza degli eventi di PML sospetta o confermata |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
• CDAI remission assessed at 12-week • PRO2 remission assessed at 12-week The CDAI and PRO2 scores will be calculated, and the APQ (Abdominal Pain Questionnaire) will be completed every 12 weeks and at Study Completion • SES-CD at 108 weeks or at early withdrawal Safety Outcome Measures (Part 1 and 2) • Weeks, 0, 4, 8, 12 and then every 12 weeks thereafter |
• CDAI di remissione valutato a 12 settimane • PRO2 di remissione valutato a 12 settimane I punteggi CDAI e PRO2 saranno calcolati, e l'APQ (Abdominal Pain Questionnaire) saranno effettuati ogni 12 settimane e al completamento dello studio • SES-CD a 108 settimane, o al ritiro anticipato Misure di esito relative alla sicurezza (parte 1 e 2) • Settimane, 0, 4, 8, 12 e poi ogni 12 settimane |
|
E.5.2 | Secondary end point(s) |
Not Applicable |
Non presente |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Not Applicable |
Non presente |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Estensione e sicurezza |
Extension and safety |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 200 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Brazil |
Canada |
Israel |
Korea, Democratic People's Republic of |
Korea, Republic of |
Mexico |
New Zealand |
Russian Federation |
Serbia |
South Africa |
Turkey |
Ukraine |
United States |
Austria |
Belgium |
Bulgaria |
Croatia |
Estonia |
France |
Germany |
Hungary |
Italy |
Latvia |
Lithuania |
Netherlands |
Poland |
Romania |
Slovakia |
Spain |
Sweden |
Switzerland |
United Kingdom |
Czechia |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date when the last patient completes the 92-week PML safety-monitoring period. |
La fine dello studio ¿ definita come la data in cui l'ultimo paziente completa le 92 settimane del periodo di sicurezza per la PML (leucoencefalopatia multifocale progressiva) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |